Deka Biosciences, a Germantown, MD-based biotech company, raised USD $20M in Series B2 funding.
The round was led by MPM BioImpact, with participation from Leaps by Bayer, O-Bio (Echo Investment Capital), Viva BioInnovator, Alexandria Venture Investments, Amana Investments, Plains Ventures, ATEM Capital and CEO John Mumm. Additionally, Detlev Biniszkiewicz, Ph.D. of MPM-BioImpact, will join the Deka board.
The company intends to use the funds to support the advancement of its pipeline and drug product manufacturing as they continue clinical trials following the receipt of a notice to proceed letter from the FDA for their investigational new drug (IND) application to evaluate DK210 (EGFR).
Led by CEO Dr. John Mumm, Deka Biosciences is a biotech company that has developed disease specific Diakines™ designed to maximize patient benefits through improved pharmacokinetics / pharmacodynamics function by the targeted accumulation of dual and complimentary cytokines into affected tissues.
FinSMES
28/09/2023